- Home
- TGNA vs RNA Comparison
TGNA vs RNA Comparison
Compare TGNA & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGNA | RNA |
|---|---|---|
| Founded | 1906 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 4.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TGNA | RNA |
|---|---|---|
| Price | $19.70 | $71.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $20.00 | ★ $69.26 |
| AVG Volume (30 Days) | 1.7M | ★ 2.4M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.10 | N/A |
| Revenue | ★ $2,876,414,000.00 | $20,868,000.00 |
| Revenue This Year | N/A | $64.11 |
| Revenue Next Year | $11.10 | $37.25 |
| P/E Ratio | $9.36 | ★ N/A |
| Revenue Growth | N/A | ★ 106.27 |
| 52 Week Low | $14.87 | $21.51 |
| 52 Week High | $21.35 | $71.86 |
Technical Indicators
Market Signals| Indicator | TGNA | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.40 | 76.01 |
| Support Level | $19.08 | $71.18 |
| Resistance Level | $19.71 | $71.79 |
| Average True Range (ATR) | 0.21 | 0.37 |
| MACD | 0.04 | -0.62 |
| Stochastic Oscillator | 89.69 | 99.16 |
Price Performance
Historical ComparisonAbout TGNA TEGNA Inc
Tegna Inc is a media company with a portfolio of broadcast stations and digital sites. The firm has television stations and radio stations in approximately U.S. markets. The company owns multicast networks of True Crime Network, Twist, and Quest. Each television station also has a robust digital presence across online, mobile, connected television, and social platforms, reaching consumers on all devices and platforms used to consume news content. It generates key revenue from advertising and marketing services, subscriptions, political advertising, and other services.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.